Why the study?
Outcomes of advanced structural heart interventions by safety-net status remain incompletely characterized, and whether TAVR with or without concomitant PCI differs by hospital safety-net status is unknown.
Does SGLT2 inhibitor therapy reduce mortality in adults with HFrEF undergoing TAVR?
Does SGLT2 inhibitor therapy reduce mortality in adults with HFrEF undergoing TAVR?
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitor therapy is associated with significantly improved survival and reduced heart failure hospitalizations at 1 year in patients with HFrEF undergoing TAVR.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Meyahnwi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: